Sara Lodi | Profiles RNS

Sara Lodi, PhD

Assistant Professor

Boston University School of Public Health

Dept of Biostatistics

PhD, London School of Hygiene & Tropical Medicine
MSc, University of Southampton

Sara Lodi is an Assistant Professor in Biostatistics at Boston University School of Public Heath. She obtained her PhD in Medical Statistics at the London School of Hygiene and Tropical Medicine in 2009, UK. Her research focuses on clinical epidemiology and comparative effectiveness research using routinely collected heath data, particularly in the area of HIV. Methodologically, she focuses on statistical techniques for causal inference to estimate effects of interventions along the HIV continuum of care. She has published many articles on behalf of large international collaborations of HIV cohorts such as CASCADE, COHERE and the HIV-CAUSAL Collaboration.

BU Sponsored Research

Forecasting the Impact of Correction-based MOUD in Massachusetts (FICOMM)
12/01/2017 - 11/30/2018 (PI)
Boston Medical Center Corporation Ntl Drug Ctrl Policy

Yr	Title	Project-Sub Proj	Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

Lodi S, Günthard HF, Dunn D, Garcia F, Logan R, Jose S, Bucher HC, Scherrer AU, Schneider MP, Egger M, Glass TR, Reiss P, van Sighem A, Boender TS, Phillips AN, Porter K, Hawkins D, Moreno S, Monge S, Paraskevis D, Simeon M, Vourli G, Sabin C, Hernán MA. Effect of immediate initiation of antiretroviral treatment on the risk of acquired HIV drug resistance. AIDS. 2018 Jan 28; 32(3):327-335. PMID: 29135583.
Caniglia EC, Phillips A, Porter K, Sabin CA, Winston A, Logan R, Gill J, Vandenhende MA, Barger D, Lodi S, Moreno S, Arribas JR, Pacheco A, Cardoso SW, Chrysos G, Gogos C, Abgrall S, Costagliola D, Meyer L, Seng R, van Sighem A, Reiss P, Muga R, Hoyos SP, Braun D, Hauser C, Barrufet P, Leyes M, Tate J, Justice A, Hernán MA. Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions. J Acquir Immune Defic Syndr. 2018 Jan 01; 77(1):102-109. PMID: 28991888.
Murray EJ, Robins JM, Seage GR, Lodi S, Hyle EP, Reddy KP, Freedberg KA, Hernán MA. Using Observational Data to Calibrate Simulation Models. Med Decis Making. 2018 02; 38(2):212-224.View Related Profiles.
Seage, George
Lodi, Sara
PMID: 29141153.
Lodi S, Costagliola D, Sabin C, Del Amo J, Logan R, Abgrall S, Reiss P, van Sighem A, Jose S, Blanco JR, Hernando V, Bucher HC, Kovari H, Segura F, Ambrosioni J, Gogos CA, Pantazis N, Dabis F, Vandenhende MA, Meyer L, Seng R, Gill MJ, Krentz H, Phillips AN, Porter K, Grinsztejn B, Pacheco AG, Muga R, Tate J, Justice A, Hernán MA. Effect of Immediate Initiation of Antiretroviral Treatment in HIV-Positive Individuals Aged 50 Years or Older. J Acquir Immune Defic Syndr. 2017 Nov 01; 76(3):311-318. PMID: 28746165.
Inequalities by educational level in response to combination antiretroviral treatment and survival in HIV-positive men and women in Europe. AIDS. 2017 01 14; 31(2):253-262. PMID: 27662557; DOI: 10.1097/QAD.0000000000001270;.
Lodi S, Sharma S, Lundgren JD, Phillips AN, Cole SR, Logan R, Agan BK, Babiker A, Klinker H, Chu H, Law M, Neaton JD, Hernán MA. The per-protocol effect of immediate versus deferred antiretroviral therapy initiation. AIDS. 2016 11 13; 30(17):2659-2663. PMID: 27782964.
Lodi S, Sharma S, Lundgren JD, Phillips AN, Cole SR, Logan R, Agan BK, Babiker A, Klinker H, Chu H, Law M, Neaton JD, Hernán MA. The per-protocol effect of immediate vs. deferred ART initiation in the START randomized trial. AIDS. 2016 Sep 06. PMID: 27603292.
Children and young people with perinatal HIV in Europe: epidemiological situation in 2014 and implications for the future. Euro Surveill. 2016; 21(10):30162. PMID: 26988197; DOI: 10.2807/1560-7917.ES.2016.21.10.30162;.
Lodi S, Phillips A, Logan R, Olson A, Costagliola D, Abgrall S, van Sighem A, Reiss P, Miró JM, Ferrer E, Justice A, Gandhi N, Bucher HC, Furrer H, Moreno S, Monge S, Touloumi G, Pantazis N, Sterne J, Young JG, Meyer L, Seng R, Dabis F, Vandehende MA, Pérez-Hoyos S, Jarrín I, Jose S, Sabin C, Hernán MA. Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study. Lancet HIV. 2015 Aug; 2(8):e335-43. PMID: 26423376; PMCID: PMC4643831.
Lodi S, del Amo J, Moreno S, Bucher HC, Furrer H, Logan R, Sterne J, Pérez-Hoyos S, Jarrín I, Phillips A, Olson A, van Sighem A, Reiss P, Sabin C, Jose S, Justice A, Goulet J, Miró JM, Ferrer E, Meyer L, Seng R, Vourli G, Antoniadou A, Dabis F, Vandenhede M, Costagliola D, Abgrall S, Hernán MA. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries. AIDS. 2014; 28(16):2461-73.

Showing 10 of 32 results. Show More

Lodi S, Dray-Spira R, Touloumi G, Braun D, Teira R, D'Arminio Monforte A, Gallois A, Zangerle R, Spire B, Dabis F, Stähelin C, Termote M, Kirk O, Chêne G, Egger M, del Amo J. Delayed HIV diagnosis and initiation of antiretroviral therapy: inequalities by educational level, COHERE in EuroCoord. AIDS. 2014 Sep 24; 28(15):2297-306. PMID: 25313585.
van der Helm JJ, Geskus R, Lodi S, Meyer L, Schuitemaker H, Gunsenheimer-Bartmeyer B, Monforte Ad, Olson A, Touloumi G, Sabin C, Porter K, Prins M. Characterisation of long-term non-progression of HIV-1 infection after seroconversion: a cohort study. Lancet HIV. 2014 Oct; 1(1):e41-8. PMID: 26423816.
Olson AD, Guiguet M, Zangerle R, Gill J, Perez-Hoyos S, Lodi S, Ghosn J, Dorrucci M, Johnson A, Sannes M, Moreno S, Porter K. Evaluation of rapid progressors in HIV infection as an extreme phenotype. J Acquir Immune Defic Syndr. 2014 Sep 01; 67(1):15-21. PMID: 24872130; PMCID: PMC4134321.
Supervie V, Ndawinz JD, Lodi S, Costagliola D. The undiagnosed HIV epidemic in France and its implications for HIV screening strategies. AIDS. 2014 Jul 31; 28(12):1797-804. PMID: 24681416; PMCID: PMC4262966.
Lodi S, Fisher M, Phillips A, De Luca A, Ghosn J, Malyuta R, Zangerle R, Moreno S, Vanhems P, Boufassa F, Guiguet M, Porter K. Symptomatic illness and low CD4 cell count at HIV seroconversion as markers of severe primary HIV infection. PLoS One. 2013; 8(11):e78642. PMID: 24244330; PMCID: PMC3828389.
Lodi S, Phillips A, Fidler S, Hawkins D, Gilson R, McLean K, Fisher M, Post F, Johnson AM, Walker-Nthenda L, Dunn D, Porter K. Role of HIV infection duration and CD4 cell level at initiation of combination anti-retroviral therapy on risk of failure. PLoS One. 2013; 8(9):e75608. PMID: 24086588; PMCID: PMC3782426.
Huang X, Lodi S, Fox Z, Li W, Phillips A, Porter K, Lutsar I, Kelleher A, Li N, Xu X, Wu H, Johnson AM. Rate of CD4 decline and HIV-RNA change following HIV seroconversion in men who have sex with men: a comparison between the Beijing PRIMO and CASCADE cohorts. J Acquir Immune Defic Syndr. 2013 Apr 01; 62(4):441-6. PMID: 23221982.
Porter K, Lodi S, Meyer L. Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion--reply. JAMA Intern Med. 2013 Mar 25; 173(6):476-7. PMID: 23529555.
Lodi S, del Amo J, d'Arminio Monforte A, Abgrall S, Sabin C, Morrison C, Furrer H, Muga R, Porter K, Girardi E. Risk of tuberculosis following HIV seroconversion in high-income countries. Thorax. 2013 Mar; 68(3):207-13. PMID: 23117980.
Lodi S, Meyer L, Kelleher AD, Rosinska M, Ghosn J, Sannes M, Porter K. Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. Arch Intern Med. 2012 Sep 10; 172(16):1252-5. PMID: 22826124.
Cain LE, Phillips A, Lodi S, Sabin C, Bansi L, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, de Wolf F, Bucher HC, Elzi L, Touloumi G, Vourli G, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Abgrall S, Costagliola D, Hernán MA. The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study. AIDS. 2012 Aug 24; 26(13):1691-705. PMID: 22546987; PMCID: PMC3647467.
del Amo J, Moreno S, Bucher HC, Furrer H, Logan R, Sterne J, Pérez-Hoyos S, Jarrín I, Phillips A, Lodi S, van Sighem A, de Wolf W, Sabin C, Bansi L, Justice A, Goulet J, Miró JM, Ferrer E, Meyer L, Seng R, Toulomi G, Gargalianos P, Costagliola D, Abgrall S, Hernán MA. Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries. Clin Infect Dis. 2012 May; 54(9):1364-72. PMID: 22460971; PMCID: PMC3404691.
del Amo J, Moreno S, Bucher HC, Furrer H, Logan R, Sterne J, Pérez-Hoyos S, Jarrín I, Phillips A, Lodi S, van Sighem A, de Wolf F, Sabin C, Bansi L, Justice A, Goulet J, Miró JM, Ferrer E, Meyer L, Seng R, Toulomi G, Gargalianos P, Costagliola D, Abgrall S, Hernán MA. Clinical Infectious Diseases. 2012; 54:1364-1372.
Lodi S, Phillips A, Touloumi G, Geskus R, Meyer L, Thiébaut R, Pantazis N, Amo JD, Johnson AM, Babiker A, Porter K. Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds <200, <350, and <500 Cells/mm³: assessment of need following changes in treatment guidelines. Clin Infect Dis. 2011 Oct; 53(8):817-25. PMID: 21921225.
Cain LE, Logan R, Robins JM, Sterne JA, Sabin C, Bansi L, Justice A, Goulet J, van Sighem A, de Wolf F, Bucher HC, von Wyl V, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Perez-Hoyos S, Muga R, Lodi S, Lanoy E, Costagliola D, Hernan MA. When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Ann Intern Med. 2011 Apr 19; 154(8):509-15. PMID: 21502648; PMCID: PMC3610527.
Lodi S, Carpenter J, Egger P, Evans S. Design of cohort studies in chronic diseases using routinely collected databases when a prescription is used as surrogate outcome. BMC Med Res Methodol. 2011 Apr 01; 11:36. PMID: 21457565; PMCID: PMC3079701.
Lodi S, Phillips A, Touloumi G, Geskus R, Meyer L, Thiebaut R, Pantazis N, del Amo J, Johnson A, Babiker A, Porter K. Time from HIV seroconversion to reaching CD4 thresholds of <200, <350 and <500 cells/mm3. Clinical Infectious diseases. 2011; 53:817-825.
Lodi S, Phillips A, Touloumi G, Pantazis N, Bucher HC, Babiker A, Chêne G, Vanhems P, Porter K. CD4 decline in seroconverter and seroprevalent individuals in the precombination of antiretroviral therapy era. AIDS. 2010 Nov 13; 24(17):2697-704. PMID: 20885283.
Lodi S, Guiguet M, Costagliola D, Fisher M, de Luca A, Porter K. Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion. J Natl Cancer Inst. 2010 Jun 02; 102(11):784-92. PMID: 20442214.
Ray M, Logan R, Sterne JA, Hernández-Díaz S, Robins JM, Sabin C, Bansi L, van Sighem A, de Wolf F, Costagliola D, Lanoy E, Bucher HC, von Wyl V, Esteve A, Casbona J, del Amo J, Moreno S, Justice A, Goulet J, Lodi S, Phillips A, Seng R, Meyer L, Pérez-Hoyos S, García de Olalla P, Hernán MA. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS. 2010 Jan 02; 24(1):123-37. PMID: 19770621; PMCID: PMC2920287.
Lodi S, Evans SJ, Egger P, Carpenter J. Is there an anti-inflammatory effect of statins in rheumatoid arthritis? Analysis of a large routinely collected claims database. Br J Clin Pharmacol. 2010 Jan; 69(1):85-94. PMID: 20078616; PMCID: PMC2830601.
Lodi S, Sebastiani P, Cocchi D, Ramoni. New Developments in Classification and Data Analysis, Springer Verlag (M. Vichi, P. Monari, S. Mignani, A. Montanari, Eds.). Bayesian clustering of gene expression dynamic: an application. 2004; 259-266.

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 32 publications over 10 distinct years, with a maximum of 5 publications in 2012 and 2014

Bar chart showing 32 publications over 10 distinct years, with a maximum of 5 publications in 2012 and 2014

Year	Publications
2004	1
2010	4
2011	4
2012	5
2013	4
2014	5
2015	1
2016	3
2017	3
2018	2

In addition to these self-described keywords below, a list of MeSH based concepts is available here.

HIV-1
Causality
Observational Studies

Contact for Mentoring:

801 Massachusetts Avenue
Boston MA 02118
Google Map

617.638.5160

Download vCard

Lodi's Networks

Click the "See All" links for more information and interactive visualizations

Concepts

See all (108) concept(s)

Co-Authors

Seage, George

See all (1) people

Similar People

See all (60) people

Same Department

Search Department